ZENTALIS PHARMACEUTICALS INC. - COMMON STOCK

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

26 Aug 2025 13:05:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

06 Aug 2025 13:05:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 Jul 2025 14:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Jun 2025 14:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

14 May 2025 13:05:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 May 2025 14:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

28 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

23 Apr 2025 13:05:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Apr 2025 14:30:34 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

26 Mar 2025 13:05:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

25 Mar 2025 13:40:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

15 Mar 2025 08:25:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Mar 2025 14:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

03 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

24 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 Feb 2025 14:42:06 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

29 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

28 Jan 2025 13:05:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

09 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Jan 2025 13:53:30 By Nasdaq GlobeNewswire